Zhang, Na
Shandong University,
China
2025 Rank: 290423
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 2365 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 290423 | 319916 |
| Total Cites | 453 | 456 |
| H-index | 9 | 10 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 19 | 19 |
| Number of Single+First+Last Authored Papers | 117 | 117 |
| Total Cites to Single+First+Last Authored Papers | 389 | 391 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 412 | 415 |
| Ratio of Total Citations to Distinct Citing Papers | 1.10 | 1.10 |
| Self-Citation Percentage |
0.66%
|
|
Zhang, Na
Ministry of Education of the People's Republic of China,
China
2024 Rank: 228872
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1786 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 228872 | 267636 |
| Total Cites | 464 | 473 |
| H-index | 10 | 10 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 21 | 21 |
| Number of Single+First+Last Authored Papers | 117 | 117 |
| Total Cites to Single+First+Last Authored Papers | 391 | 397 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 434 | 440 |
| Ratio of Total Citations to Distinct Citing Papers | 1.07 | 1.08 |
| Self-Citation Percentage |
1.90%
|
|
Zhang, Na
Shandong University,
China
2023 Rank: 158241
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1169 out of 140593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 158241 | 182056 |
| Total Cites | 534 | 545 |
| H-index | 12 | 12 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 38 | 38 |
| Number of Single+First+Last Authored Papers | 117 | 117 |
| Total Cites to Single+First+Last Authored Papers | 455 | 465 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 474 | 480 |
| Ratio of Total Citations to Distinct Citing Papers | 1.13 | 1.14 |
| Self-Citation Percentage |
2.02%
|
|
Zhang, Na
Shandong University,
China
2022 Rank: 158503
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1166 out of 134745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 158503 | 182363 |
| Total Cites | 510 | 529 |
| H-index | 12 | 12 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 35 | 35 |
| Number of Single+First+Last Authored Papers | 117 | 117 |
| Total Cites to Single+First+Last Authored Papers | 409 | 422 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 448 | 459 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.15 |
| Self-Citation Percentage |
3.59%
|
|
Zhang, Na
Shandong University,
China
2021 Rank: 145580
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1071 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 145580 | 167335 |
| Total Cites | 797 | 830 |
| H-index | 15 | 15 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 64 | 65 |
| Number of Single+First+Last Authored Papers | 117 | 117 |
| Total Cites to Single+First+Last Authored Papers | 632 | 652 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 690 | 709 |
| Ratio of Total Citations to Distinct Citing Papers | 1.16 | 1.17 |
| Self-Citation Percentage |
3.98%
|
|
Zhang, Na
Shandong University,
China
2020 Rank: 219463
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1553 out of 94611 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 219463 | 258656 |
| Total Cites | 360 | 365 |
| H-index | 10 | 10 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 39 | 40 |
| Number of Single+First+Last Authored Papers | 72 | 72 |
| Total Cites to Single+First+Last Authored Papers | 303 | 308 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 316 | 319 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.14 |
| Self-Citation Percentage |
1.37%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.